ApplyComparisons
Make up to three selections, then save.0 of 3 selected
0 of 3 selected
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Low
Med
High
| Open | -- |
|---|---|
| High | -- |
| Low | -- |
| Bid | -- |
| Offer | -- |
| Previous close | -- |
| Average volume | -- |
|---|---|
| Shares outstanding | 64.24m |
| Free float | 64.24m |
| P/E (TTM) | 12.88 |
| Market cap | 122.38bn DKK |
| EPS (TTM) | 147.88 DKK |
--
More ▼
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
- Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
- Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Genmab Portfolio Prioritization Update
- Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
- Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
- Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
- Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
More ▼
- Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
- Genmab Portfolio Prioritization Update
- Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
- Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
- Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R²) in Patients with Relapsed or Refractory Follicular Lymphoma
- Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
- Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
More ▼
